IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Time to Buy?

Shares of IPSEN (OTCMKTS:IPSEY) gapped up before the market opened on Tuesday . The stock had previously closed at $43.85, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 153 shares traded.

Analyst Ratings Changes

A number of research firms have recently commented on IPSEY. Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. HC Wainwright assumed coverage on IPSEN in a report on Friday, June 5th. They issued a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, IPSEN has a consensus rating of “Hold”.

IPSEN Price Performance

The firm’s fifty day moving average is $47.45 and its 200 day moving average is $43.56.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).